|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1995-12-26
|
|
pubmed:abstractText |
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-1740682,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-1999004,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-2496470,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-2681557,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-2711203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-2711204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-7526467,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-7678854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-7931479,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-7931480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-7947109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-8075049,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-8113840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-8229125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-8315421,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-8334629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-8400323,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7577478-8430312
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1256-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7577478-Adult,
pubmed-meshheading:7577478-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7577478-Breast Neoplasms,
pubmed-meshheading:7577478-Carboplatin,
pubmed-meshheading:7577478-Female,
pubmed-meshheading:7577478-Follow-Up Studies,
pubmed-meshheading:7577478-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:7577478-Humans,
pubmed-meshheading:7577478-Leukopenia,
pubmed-meshheading:7577478-Neoplasm Metastasis,
pubmed-meshheading:7577478-Phlebitis,
pubmed-meshheading:7577478-Remission Induction,
pubmed-meshheading:7577478-Salvage Therapy,
pubmed-meshheading:7577478-Treatment Outcome,
pubmed-meshheading:7577478-Vinblastine
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
|
|
pubmed:affiliation |
Istituto di Medicina Interna, Università di Cagliari, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
